keyword
MENU ▼
Read by QxMD icon Read
search

Brentuximab

keyword
https://www.readbyqxmd.com/read/29025292/-brentuximab-vedotin-treatment-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-a-hungarian-retrospective-study
#1
Zsuzsa Molnár, László Imre Pinczés, Klára Piukovics, Ildikó Istenes, Krisztina Wolf, Zoltán Csukly, Árpád Szomor, Árpád Illés, Zsófia Miltényi
INTRODUCTION: The treatment of relapsed or refractory Hodgkin lymphoma is still a major therapeutic challenge. The use of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, represents a promising approach for these patients, however clinical outcomes have not yet been evaluated in Hungary. AIM: Our aim was to assess the efficacy, safety and outcome of brentuximab vedotin treatment in Hungarian Hodgkin lymphoma patients. METHOD: In this retrospective case note review we enrolled patients at 6 clinical sites countrywide who were diagnosed with Hodgkin lymphoma and received brentuximab vedotin between 1 January 2013 and 31 December 2016...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29025289/-the-role-of-autologous-hemopoietic-stem-cell-transplantation-in-t-cell-lymphoma-hungarian-data
#2
Árpád Szomor, Renáta Csalódi, Szabolcs Kosztolányi, Ágnes Nagy, Judit Pammer, Orsolya Tóth, Hajna Losonczy, Hussain Alizadeh, Zsófia Miltényi, Péter Reményi, Klára Piukovics
T-cell lymphoma is a poor prognostic hematological malignancy. The generally used - not sufficiently effective - induction chemotherapy should be improved with consolidative autologous hemopoetic stem cell transplantation. The authors describe the role, place and effectiveness of transplantation in this disorder. One hundred thirty three autologous stem cell transplantations were performed in the last 22 years in Hungary. Detailed results are available from the last 6 years. In this period 43 transplantations were carried out in 4 Hungarian centers...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28991893/treatment-patterns-and-costs-of-care-for-patients-with-relapsed-and-refractory-hodgkin-lymphoma-treated-with-brentuximab-vedotin-in-the-united-states-a-retrospective-cohort-study
#3
Shelagh M Szabo, Ishan Hirji, Karissa M Johnston, Ariadna Juarez-Garcia, Joseph M Connors
OBJECTIVES: Although brentuximab vedotin (BV) has changed the management of patients with relapsed or refractory Hodgkin lymphoma (RRHL), little information is available on routine clinical practice. We identified treatment patterns and costs of care among RRHL patients in the United States (US) treated with BV. METHODS: A retrospective observational study of adults initiating BV for RRHL from 2011-2015, with ≥6 months of data prior to and following BV initiation, was conducted...
2017: PloS One
https://www.readbyqxmd.com/read/28980004/brentuximab-vedotin-for-patients-with-refractory-lymphomatoid-papulosis-an-analysis-of-phase-2-results
#4
Daniel J Lewis, Rakhshandra Talpur, Auris O Huen, Michael T Tetzlaff, Madeleine Duvic
Importance: Brentuximab vedotin is a monomethyl auristatin E-conjugated monoclonal antibody directed against CD30. It represents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment. Objective: To assess the efficacy and safety of brentuximab vedotin for the treatment of LyP. Design, Setting, and Participants: In this study conducted at The University of Texas MD Anderson Cancer Center from May 10, 2011, to March 31, 2017, a total of 12 patients with LyP received brentuximab vedotin...
October 4, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28978839/treatment-strategy-for-patients-with-hodgkin-lymphoma
#5
Isao Yoshida
Although Hodgkin lymphoma is a disease with a low incidence rate, there is a significant social resources perspective associated with this disease to ensure that adolescents and young adults are adequately treated and receive social reintegration. Consequently, Hodgkin lymphoma is considered an important disease in the field of oncology. Combined modality therapy, which combines chemotherapy and radiotherapy, has resulted in cure rates of more than 80% in patients with early stages of this disease, although long-term sequelae remain a problem...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28974506/five-year-results-of-brentuximab-vedotin-in-patients-with-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma
#6
Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L Bartlett, Joseph D Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M Connors, Keenan Fenton, Dirk Huebner, Juan M Pinelli, Dana A Kennedy, Andrei Shustov
This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (N=58), no progressions were observed beyond 40 months, and median OS was not reached...
October 3, 2017: Blood
https://www.readbyqxmd.com/read/28967896/post-autologous-transplant-maintenance-therapies-in-lymphoma-current-state-and-future-directions
#7
REVIEW
P A Riedell, M R Bishop
Disease relapse following high-dose chemotherapy and autologous stem cell transplant (ASCT) remains the principal cause of mortality in patients with relapsed or refractory lymphomas. In an effort to prevent post-ASCT relapse, a number of studies have evaluated the role of maintenance therapy with varying success. In diffuse large B-cell lymphoma, studies evaluating maintenance rituximab (MR) following ASCT failed to demonstrate improved outcomes. In follicular lymphoma, MR was associated with an improvement in PFS; however, no overall survival (OS) benefit was noted...
October 2, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28961828/nivolumab-for-relapsed-or-refractory-hodgkin-lymphoma-real-life-experience
#8
H Beköz, N Karadurmus, S Paydas, A Türker, T Toptas, T Firatli Tuglular, M Sönmez, Z Gülbas, E Tekgündüz, A H Kaya, M Özbalak, N Tastemir, L Kaynar, R Yildirim, I Karadogan, M Arat, F Pepedil Tanrikulu, V Özkocaman, H Abali, M Turgut, M Kurt Yüksel, M Özcan, M H Dogu, S Kabukçu Hacioglu, I Barista, M Demirkaya, F D Köseoglu, S K Toprak, M Yilmaz, H C Demirkürek, O Demirkol, B Ferhanoglu
Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey...
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28949403/brentuximab-vedotin-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-who-are-ineligible-for-autologous-stem-cell-transplant-a-germany-and-uk-retrospective-study
#9
Paul J Bröckelmann, Erin A Zagadailov, Shelby L Corman, Viktor Chirikov, Courtney Johnson, Cynthia Macahilig, Brian Seal, Mehul R Dalal, Tim Illidge
OBJECTIVE: Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multi-agent chemotherapy is not an option. The objective of this study was to describe real-world outcomes with BV in rrHL patients considered ASCT-ineligible or who refuse ASCT. METHODS: This was a retrospective medical chart review study that enrolled patients ≥18 years old who were initially diagnosed with HL between 1 January 2008 and 30 June 2014, considered ASCT-ineligible, and treated in routine care with BV for progressive disease after multi-drug chemotherapy regimens...
September 26, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28946015/peripheral-t-cell-lymphomas-focusing-on-novel-agents-in-relapsed-and-refractory-disease
#10
REVIEW
Alessandro Broccoli, Lisa Argnani, Pier Luigi Zinzani
Patients with relapsed or refractory peripheral T-cell lymphoma display a dismal prognosis and their therapy represents an unmet medical need, as the best treatment strategy is yet to be determined. Exciting data on novel targeted agents are now emerging from recently concluded and ongoing clinical trials in patients with relapsed and refractory PTCL. Four recently approved compounds are used as single agents: pralatrexate, a novel antifolate agent; romidepsin and belinostat, both histone deacetylase (HDAC) inhibitors; brentuximab vedotin, an anti-CD30 drug-conjugated monoclonal antibody...
September 18, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28941150/brentuximab-vedotin-exerts-profound-antiproliferative-and-pro-apoptotic-efficacy-in-cd30-positive-as-well-as-cocultured-cd30-negative-germ-cell-tumour-cell-lines
#11
Stefan Schönberger, Cornelius van Beekum, Barbara Götz, Daniel Nettersheim, Hubert Schorle, Dominik T Schneider, Anna Casati, Rogerio B Craveiro, Gabriele Calaminus, Dagmar Dilloo
Prognosis in patients suffering from high-risk, refractory and relapsed germ cell tumours (GCT) often comprising of CD30-positive embryonal carcinoma (EC) components remains poor. Thus, novel treatment strategies are warranted. The antibody-drug conjugate (ADC) brentuximab vedotin delivers the potent antimitotic drug monomethyl auristatin E (MMAE) to CD30-expressing tumour cells. After CD30 binding, internalization and intracellular linker cleavage cytotoxic MMAE can efflux and eradicate neighbouring CD30-negative cells...
September 22, 2017: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/28932193/safety-profile-of-anticancer-and-immune-modulating-biotech-drugs-used-in-a-real-world-setting-in-campania-region-italy-bio-cam-observational-study
#12
Cristina Scavone, Liberata Sportiello, Maria G Sullo, Carmen Ferrajolo, Rosanna Ruggiero, Maurizio Sessa, Pasquale M Berrino, Gabriella di Mauro, Liberato Berrino, Francesco Rossi, Concetta Rafaniello, Annalisa Capuano
Objectives: To investigate the occurrence of adverse events (AEs) in naïve patients receiving biotech drugs. Design: A prospective observational study. Setting: Onco-hematology, Hepato-gastroenterology, Rheumatology, Dermatology, and Neurology Units in Campania Region (Italy). Participants: 775 patients (53.81% female) with mean age 56.0 (SD 15.2). The mean follow-up/patient was 3.48 (95% confidence interval 3.13-3.84). Main outcome measures: We collected all AEs associated to biotech drugs, including serious infections and malignancies...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28918995/cutaneous-adverse-events-of-targeted-therapies-for-hematolymphoid-malignancies
#13
REVIEW
Julia D Ransohoff, Bernice Y Kwong
The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. In this article we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs observed during treatment with targeted therapies for hematologic and lymphoid malignancies...
July 14, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28912294/brentuximab-is-it-time-for-a-new-b-in-abvd
#14
Deborah M Stephens
No abstract text is available yet for this article.
September 14, 2017: Blood
https://www.readbyqxmd.com/read/28885612/understanding-cd30-biology-and-therapeutic-targeting-a-historical-perspective-providing-insight-into-future-directions
#15
REVIEW
C A van der Weyden, S A Pileri, A L Feldman, J Whisstock, H M Prince
CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Given the restriction of CD30 to certain tumor types, the logical extension of this has been to attempt to exploit it as a therapeutic target...
September 8, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28874350/prognostic-significance-of-baseline-metabolic-tumor-volume-in-relapsed-and-refractory-hodgkin-lymphoma
#16
Alison J Moskowitz, Heiko Schöder, Somali Gavane, Katie L Thoren, Martin Fleisher, Joachim Yahalom, Susan J McCall, Briana R Cadzin, Stephanie Y Fox, John Gerecitano, Ravinder Grewal, Paul A Hamlin, Steven M Horwitz, Anita Kumar, Matthew Matasar, Andy Ni, Ariela Noy, M Lia Palomba, Miguel-Angel Perales, Carol S Portlock, Craig Sauter, David Straus, Anas Younes, Andrew D Zelenetz, Craig H Moskowitz
Identification of prognostic factors for patients with relapsed or refractory (rel/ref) Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase II study of PET-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carboplatin, etoposide (augICE) we assessed clinical factors, quantitative PET assessments, and cytokines/chemokine values. Transplant-eligible patients with rel/ref HL received 2 (cohort 1) or 3 (cohort 2) cycles of weekly BV; PET-negative (Deauville ≤ 2) patients proceeded to autologous stem cell transplant (ASCT) while PET-positive patients received augICE before ASCT...
September 5, 2017: Blood
https://www.readbyqxmd.com/read/28857136/results-of-a-multicentre-uk-wide-retrospective-study-evaluating-the-efficacy-of-brentuximab-vedotin-in-relapsed-refractory-classical-hodgkin-lymphoma-in-the-transplant-naive-setting
#17
Toby A Eyre, Elizabeth H Phillips, Kim M Linton, Shireen Kassam, Adam Gibb, Suzanne Allibone, John Radford, Karl Peggs, Cathy Burton, Gillian Stewart, Rifca LeDieu, Catherine Booth, Wendy L Osborne, Fiona Miall, David W Eyre, Kirit M Ardeshna, Graham P Collins
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed...
August 31, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28805662/clinical-and-immunological-responses-after-cd30-specific-chimeric-antigen-receptor-redirected-lymphocytes
#18
Carlos A Ramos, Brandon Ballard, Huimin Zhang, Olga Dakhova, Adrian P Gee, Zhuyong Mei, Mrinalini Bilgi, Meng-Fen Wu, Hao Liu, Bambi Grilley, Catherine M Bollard, Bill H Chang, Cliona M Rooney, Malcolm K Brenner, Helen E Heslop, Gianpietro Dotti, Barbara Savoldo
BACKGROUND: Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS: We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30...
September 1, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28805086/brentuximab-vedotin-therapy-for-cd30-positive-cutaneous-t-cell-lymphoma-a-targeted-approach-to-management
#19
Julia J Scarisbrick
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Response rates >75% with manageable adverse effects in refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma led to accelerated approval for both. Phase II studies in CD30-expressing CTCL followed and showed similar efficacy, which was ratified in a Phase III trial of BV versus physician's choice (methotrexate or bexarotene) showing significant improved responses without increase in severe adverse effects although peripheral neuropathy is frequent...
August 14, 2017: Future Oncology
https://www.readbyqxmd.com/read/28775121/italian-real-life-experience-with-brentuximab-vedotin-results-of-a-large-observational-study-on-40-relapsed-refractory-systemic-anaplastic-large-cell-lymphoma
#20
Alessandro Broccoli, Cinzia Pellegrini, Alice Di Rocco, Benedetta Puccini, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Carmelo Carlo-Stella, Stefan Hohaus, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Angela Gravetti, Giuseppe Gritti, Annalisa Arcari, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Virginia Naso, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Sergio Storti, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani, Pier Luigi Zinzani
From November 2012 to July 2014, brentuximab vedotin was available in Italy for patients with relapsed systemic anaplastic large cell lymphoma outside a clinical trial context according to the national law 648/96. A large Italian observational retrospective study was conducted on the use of brentuximab vedotin in the everyday clinical practice to check if clinical trial results are confirmed even in a real life context. Primary endpoint was the best response; secondary endpoints were the overall response rate at the end of the treatment, duration of response, survival and the safety profile...
August 3, 2017: Haematologica
keyword
keyword
19655
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"